AstraZeneca

Who Is AstraZeneca?

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas: Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

When was AstraZeneca Founded?

Astra was founded in Sweden in 1913. Zeneca Group PLC was formed when ICI demerged three of its businesses. In 1999 Astra and Zeneca merge, creating AstraZeneca.

Where is AstraZeneca Located?

AstraZeneca is headquartered in Cambridge, United Kingdom with two primary locations in North America – Gaithersburg, Maryland and Wilmington, Delaware – where the majority of their US employees come together on global projects.

Who Owns AstraZeneca?

The largest shareholders of AstraZeneca are owned by institutional investors including T. Rowe Price Associates, Inc, Wellington Management Co. LLP, PRIMECAP Management Co, Capital Research & Management Company, GQG Partners LLC, Jennison Associates LLC, and Fidelity Management & Research Company.

What Vaccines Are Made By AstraZeneca?

AstraZeneca is the maker of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal), an intranasal vaccine for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is also known as LAIV (Live Attenuated Intranasal Vaccine).

FluMist® Quadrivalent is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy. Most common side effects reported were runny nose or nasal congestion, sore throat, and fever >100°F. For additional Important Safety Information and full Prescribing Information, visit here.

Flumist is sold through distributors. Medical Practices interested in adding Flumist ( LAIV ) to their flu vaccine offerings can receive additional benefits on Flumist purchases through an  MPPG membership.

References:
1. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2019-20 influenza season. MMWR. 2019;68:1–21.

2. AAP News. No flu vaccine preference for 2019-’20 season. https://www.aapublications.org/news. Accessed 11/7/19.

FLUMIST is a registered trademark of the AstraZeneca group of companies.
©2019 AstraZeneca. All rights reserved. US-34627 Last Updated 12/19

AstraZeneca Vaccines Ordering

For information regarding influenza, ordering, dosing and administration of FluMist® Quadrivalent, and recommendations from the AAP and ACIP, visit here.

For reimbursement support services for FluMist® Quadrivalent, visit here.